Study title:
Li BUK, Besedovsky A. Across the developmental continuum of irritable bowel syndrome: Clinical and pathophysiologic considerations. Curr Gastroenterol Rep. June 1, 2004, 247-53Li BUK, Besedovsky A. Across the developmental continuum of irritable bowel syndrome: Clinical and pathophysiologic considerations. Curr Gastroenterol Rep. June 1, 2004, 247-53
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Digestive System Diseases [C06]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: SIMETICONE |
ATC code: A02DA01 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|